《中国药物性肝损伤诊治指南(2023年版)》更新要点解读  

Interpretation of the updated key points of Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)

作　　者：孟尧 张萌萌[1] 郭甜甜 赵新颜[1] Meng Yao;Zhang Mengmeng;Guo Tiantian;Zhao Xinyan(Liver Research Center,Beijing Friendship Hospital,Capital Medical University,National Clinical Research Center for Digestive Diseases,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院肝病中心,国家消化系统疾病临床医学研究中心,北京100050

出　　处：《中国肝脏病杂志（电子版）》2023年第4期1-5,共5页Chinese Journal of Liver Diseases：Electronic Version

基　　金：科技部科技创新2030—“新一代人工智能”重大课题(2021ZD0113200)。

摘　　要：药物性肝损伤(drug-induced liver injury,DILI)是一种严重的药物不良反应,目前仍缺乏客观且特异性诊断指标及有效治疗药物。近年来DILI领域的研究产生了新观点和新证据,基于此中华医学会肝病学分会药物性肝病学组依据新近研究进展更新了2015版药物性肝损伤指南。本文拟从13个方面对新旧版DILI指南进行对比解读,以更好地理解指南、践行指南。Drug-induced liver injury(DILI)is a serious adverse drug reaction.At present,there is still a lack of objective and specific diagnostic criteria and effective drugs.In recent years,new ideas and evidence have been proposed in the field of DILI.Based on this,Study Group of Drug-Induced Liver Disease,Chinese Medical Association for the Study of Liver Diseases updated the guideline(2015 version)for drug-induced liver injury based on the latest research progress.This paper intends to make a comparative interpretation of the new and old DILI guidelines from 13 aspects in order to intensify the understanding and practise the guideline.

关 键 词：药物性肝损伤 指南 对比 诊断 治疗 

分 类 号：R575[医药卫生—消化系统]